We are pleased to announce that, in response to our standing request for important SMA clinical development and programme updates, Roche has shared an update on the RAINBOWFISH clinical trial, for which results from the primary analysis were presented at the 28th World Muscle Society (WMS) Congress.
We are pleased to share the latest community update from Roche with several topics that are relevant to our SMA Community.
We are pleased to share the latest community update from Roche, announcing that the CHMP (Committee for Medicinal Products for Human Use) at the European Medicines Agency (EMA) has recommended the approval of an indication extension for risdiplam (Evrysdi), for all ages, from birth.
Biocad, a Russian biotechnology company, shares a community statement on its gene therapy product, ANB-004, which is being developed to treat SMA.